早孕期代谢物生物标志物预测早产型子痫前期:根据母亲体重指数呈现差异化预测
本研究为观察性病例对照研究,纳入2501例单胎妊娠孕妇,于11-13周采集血浆分析50种代谢物,比较1635例对照与106例早产型子痫前期病例。发现13种代谢物及7种氨基酸比值与早产型子痫前期相关,且部分代谢物的预测性能因体重指数分层而异,支持存在不同母亲风险表型的观点。
要点
- 13种代谢物与早产型子痫前期相关,其中6种关联尤其显著(P<.01)。
- 7种涉及谷氨酰胺或鸟氨酸的氨基酸比值在病例与对照间差异显著(P<.01)。
- 鸟氨酸及相关比值仅在体重指数<25 kg/m2组与早产型子痫前期强关联。
核心结论
- 孕11-13周时,单一代谢物及与精氨酸生物利用度和一氧化氮合酶通路相关的氨基酸比值与早产型子痫前期风险相关。
- 观察到根据体重指数分类的差异化预测,支持存在不同母亲风险表型的观点。
- 未来子痫前期预测研究应考虑不同母亲风险表型的可能性,以改善病因学和预后理解及筛查试验的临床效用。
研究设计与样本
- 观察性病例对照研究,源自2010至2015年在伦敦国王学院医院常规首次就诊孕妇中开展的大型前瞻性妊娠并发症早期预测研究。
- 对2501例单胎妊娠孕妇的11-13周血浆样本采用靶向液相色谱-质谱法分析预选代谢物,获得50种代谢物的高质量定量数据。
- 将参与精氨酸生物合成和一氧化氮合酶通路的氨基酸水平比值加入生物标志物列表。
- 胎盘生长因子和妊娠相关血浆蛋白A作为对照风险预测指标。
- 分析纳入1635例对照和106例早产型子痫前期妊娠,数据以中位数倍数归一化。
主要发现
- 13种代谢物水平与整个研究人群的早产型子痫前期相关(P<.05),其中6种关联尤其显著(P<.01):2-羟基-(2/3)-甲基丁酸、25-羟基维生素D3、2-羟基丁酸、丙氨酸、十二碳酰基肉碱和1-(1Z-十八碳烯基)-2-油酰-sn-甘油-3-磷酸胆碱。
- 7种氨基酸比值的倍数变化在病例与对照间也显著不同(P<.01),所有比值均涉及谷氨酰胺或鸟氨酸。
- 鸟氨酸(P<.001)和几种鸟氨酸相关比值(P<.0001至P<.01)仅在体重指数<25 kg/m2组与早产型子痫前期强关联。
- 十二碳酰基肉碱和3种谷氨酰胺比值在体重指数≥30 kg/m2组尤其具有预测性(P<.01)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prediction of preeclampsia risk is key to informing effective maternal care. Current screening for preeclampsia at 11 to 13 weeks of gestation using maternal demographic characteristics and medical history with measurements of mean arterial pressure, uterine artery pulsatility index, and serum placental growth factor can identify approximately 75% of women who develop preterm preeclampsia with delivery at <37 weeks of gestation. Further improvements to preeclampsia screening tests will likely require integrating additional biomarkers. Recent research suggests the existence of distinct maternal risk profiles. Therefore, biomarker evaluation should account for the possibility that a biomarker only predicts preeclampsia in a specific maternal phenotype. OBJECTIVE: This study aimed to verify metabolite biomarkers as preterm preeclampsia predictors early in pregnancy in all women and across body mass index groups. STUDY DESIGN: Observational case-control study drawn from a large prospective study on the early prediction of pregnancy complications in women attending their routine first hospital visit at King's College Hospital, London, United Kingdom, in 2010 to 2015. Pregnant women underwent a complete first-trimester assessment, including the collection of blood samples for biobanking. In 11- to 13-week plasma samples of 2501 singleton pregnancies, the levels of preselected metabolites implicated in the prediction of pregnancy complications were analyzed using a targeted liquid chromatography-mass spectrometry method, yielding high-quality quantification data on 50 metabolites. The ratios of amino acid levels involved in arginine biosynthesis and nitric oxide synthase pathways were added to the list of biomarkers. Placental growth factor and pregnancy-associated plasma protein A were also available for all study subjects, serving as comparator risk predictors. Data on 1635 control and 106 pregnancies complicated by preterm preeclampsia were considered for this analysis, normalized using multiples of medians. Prediction analyses were performed across the following patient strata: all subjects and the body mass index classes of <25, 25 to <30, and ≥30 kg/m2. Adjusted median levels were compared between cases and controls and between each body mass index class group. Odds ratios and 95% confidence intervals were calculated at the mean ±1 standard deviation to gauge clinical prediction merits. RESULTS: The levels of 13 metabolites were associated with preterm preeclampsia in the entire study population (P<.05) with particularly significant (P<.01) associations found for 6 of them, namely, 2-hydroxy-(2/3)-methylbutyric acid, 25-hydroxyvitamin D3, 2-hydroxybutyric acid, alanine, dodecanoylcarnitine, and 1-(1Z-octadecenyl)-2-oleoyl-sn-glycero-3-phosphocholine. Fold changes in 7 amino acid ratios, all involving glutamine or ornithine, were also significantly different between cases and controls (P<.01). The predictive performance of some metabolites and ratios differed according to body mass index classification; for example, ornithine (P<.001) and several ornithine-related ratios (P<.0001 to P<.01) were only strongly associated with preterm preeclampsia in the body mass index of <25 kg/m2 group, whereas dodecanoylcarnitine and 3 glutamine ratios were particularly predictive in the body mass index of ≥30 kg/m2 group (P<.01). CONCLUSION: Single metabolites and ratios of amino acids related to arginine bioavailability and nitric oxide synthase pathways were associated with preterm preeclampsia risk at 11 to 13 weeks of gestation. Differential prediction was observed according to body mass index classes, supporting the existence of distinct maternal risk profiles. Future studies in preeclampsia prediction should account for the possibility of different maternal risk profiles to improve etiologic and prognostic understanding and, ultimately, clinical utility of screening tests.
引用
- Tuytten R, Syngelaki A, Thomas G, et al. First-trimester preterm preeclampsia prediction with metabolite biomarkers: differential prediction according to maternal body mass index. Am J Obstet Gynecol. 2022. PMID: 36539025. doi:10.1016/j.ajog.2022.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。